u/noor_ivaturi

The muscle cramps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

employer plans have their own criteria and their own appeals

Which member state?

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

EU-wide advice is almost always wrong somewhere

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.

Are you comparing against a GLP-1 monotherapy result?

Agreed, and the combination arms are where the interesting numbers actually live.

reimbursement is national, not European, and that is the whole board

Spent three weeks on what turned out to be a quantity limit rather than a coverage question.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

Which phase 2 arm are you quoting, and at what week?

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

a lot of the confident posting here is extrapolation

Are you tracking heart rate at all?

Watched heart rate on a wearable across twelve weeks because the threads said to.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.